Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 6 relevant journals, 436 Scientific conference proceedings and 108 National symposiums are presently dedicated exclusively to Benign Prostatic Hyperplasia and and about 157 Open Access Articles are being published on Benign Prostatic Hyperplasia.
BPH occurs in almost all men as they age. BPH is not cancer. An enlarged prostate can be a nuisance. But it is usually not a serious problem. About half of all men older than 75 have some symptoms.Today, the interdisciplinary care of prostate cancer has become a reality, and urologists along with radiation, surgical, and medical oncologists are all involved in the management of these patients. In order to provide optimal care, it is essential that all members of the treatment team stay up-to-date on current trends and emerging data, not just in their own area, but also in the related specialties such as Prostatitis Treatment & Management, Benign Prostatic Hyperplasia, Prostate Cancer: Clinical Urology, Histology of prostate cancer and Living and Managing Prostate Cancer.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and Importance
Benign Prostatic Hyperplasia Conference provides the scope for opportunities to learn progressed by international scientists and academicians.Benign Prostatic Hyperplasia also called BPH, is a condition in men where there is an enlargement of prostate gland which is noncancerous. It is also known as benign prostatic obstruction and benign prostatic hypertrophy. BPH starts at the age of 30 and most commonly causes symptoms only after the age of 50. When the prostate enlarges, it may constrict the flow of urine and symptoms like Decreased force of stream - The subjective loss of force of the urinary stream over time , Dribbling - The loss of small amounts of urine due to a poor urinary stream , Hesitancy - Difficulty initiating the urinary stream; interrupted, weak stream , Incomplete bladder emptying - The feeling of persistent residual urine, regardless of the frequency of urination , Straining - The need strain or push (Valsalva maneuver) to initiate and maintain urination in order to more fully evacuate the bladder , Urinary urgency and Urinary frequency.
Market Analysis
The market for therapies that treat benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms will fluctuate over the next decade as modest growth from 2013 to 2017 will be negated by a 7.1 percent annual decline from 2010 to 2013 and by a subsequent market decline from 2017 to 2020. Owing to the generic erosion of key agents, the BPH drug market will decrease from more than $4.8 billion in 2010 to just under $4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
International symposium and workshops
Prostate cancer world conference , August 18-21 -2015, Cairns, Queensland, Australia.
Global Congress on Prostate Cancer , February5-7,2015 -Rome, Italy.
Genitourinary Cancers Symposium, February 26-28, 2015, Orlando ,Florida.
Advanced Prostate Cancer Consensus Conference, March 12-14, 2015, St Galen Switzerland.
List of Best International Conferences
Pancreatic and Colorectal Cancer Conference
March 29-30, 2016 Atlanta, USA.
4th Blood Malignancies Conference
April 18-20, 2016 Dubai, UAE.
Gynecologic Oncology Conference
May 19-21, 2016 San Antonio, USA.
2nd Antimicrobial Agents and Chemotherapy Conference
June 6-7, 2016 Dallas, USA.
Cancer Diagnostics Conference
June 13-15, 2016 Rome, Italy.
10 Global Oncologists Conference
July 11-13, 2016 Cologne, Germany.
11th Oncology and Oncologists Conference
July 11-13, 2016 Kuala Lumpur, Malaysia
Melanoma and Carcinoma Conference
July 14-15, 2016 Brisbane, Australia.
Neuro Onclogy Conference
July 21-23, 2016 Brisbane, Australia.
Thyroid Cancer Conference
Aug 1-3, 2016 Toronto, Canada.
Oral, Mouth and Throat Cancer Conference
Aug 18-20, 2016 Portland, Oregon.
Molecular & Cancer Biomarkers Conference
Sept 15-17, 2016 Berlin, Germany.
Cervical Cancer Conference
Sept 22-23, 2016 Vienna, Austria.
Radiation Oncology Conference
Sep 26-28, 2016 Valencia, Spain.
12th Cancer Therapy Conference
Sept 26-28, 2016 London, UK.
13th Oncologists and Cancer Therapy Conference
Oct 17-19, 2016 Dubai, UAE.
Mesothelioma Conference
Nov 3-4, 2016 Valencia, Spain.
Leukemia and Bonemarrow Tranplantation Conference
Nov 10-12, 2016 Istanbul, Turkey.
14th Cancer Therapy Conference
Dec 8-10, 2016 Baltimore, USA.
Relevant Society and Associations
American Cancer Society.
Prostate Cancer Foundation.
Cancer Research UK.
British Association of Urological Surgeons (BAUS).
National Cancer Institute.
Prostate Cancer UK.
Prostate Cancer Canada.
Australian Prostate cancer Research Centre.
Prostate Cancer Foundation of Australia.
Urological Association of Asia and Iranian.
List of Companies
OncoGenex.
Prostate Cancer UK.
Endo Pharmaceuticals.
Celgene.
deCODE genetics.
BTG.
Bavarian Nordic.
Exelixis.
Prostagene.
This page will be updated regularly.
This page was last updated on November 5, 2024
